Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements ...

Dry age-related macular degeneration is the most common form of the disease, affecting millions of older Americans, according to the National Eye Institute. The condition develops ...

Dry age-related macular degeneration is the most common type — it happens when small deposits form under the retina, causing ...

Patients with neovascular age‑related macular degeneration (AMD) whose retinal fluid cleared within 12 weeks of starting faricimab were more likely to have longer intervals between injections later in ...

A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr Dao Nguyen examines a vial of lutein formulation developed for potential use in eyedrop treatments. (CREDIT: Will Wright, RMIT ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.